April 20, 2026Journal of the American College of Cardiology
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Key result
IL-1β inhibition improves cardiovascular outcomes, supporting anti-inflammatory strategies in atherosclerosis.
Why the study?
Inflammatory pathways drive atherogenesis and link conventional risk factors to atherosclerosis and its complications, highlighting interleukin-1 beta as a therapeutic target in cardiovascular disease.
Comparison
Interventions that interfere with IL-1β action
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support biomarker-guided IL-1β therapy in atherosclerosis; leaves open optimal use pending dedicated randomized trials.
Key Points
- To review experimental and clinical evidence evaluating interleukin-1 beta (IL-1β) inhibition as a targeted anti-inflammatory strategy for atherosclerosis and cardiovascular disease.
- Synthesized mechanistic, translational, and clinical evidence evaluating the role of IL-1β in vascular inflammation and plaque biology.
- Evaluated the molecular mechanisms of inflammasome-mediated IL-1β activation across vascular wall cells and lesional leukocytes.
- Atherosclerotic plaque stimuli drive the molecular assembly of the inflammasome, triggering IL-1β secretion by both local vascular wall cells and infiltrating leukocytes.
- Therapeutic inhibition of IL-1β reduces major adverse cardiovascular events in clinical settings, establishing inflammation as a modifiable driver of atherogenesis.
- Biomarker-guided administration of IL-1β inhibitors offers a viable pathway toward personalized anti-inflammatory management for cardiovascular patients.
Structured PICO
I
Intervention
Interventions that interfere with interleukin-1 beta (IL-1β) action
Interleukin-1 beta is a key inflammatory mediator in atherosclerosis, and targeting it represents a promising therapeutic strategy to improve cardiovascular outcomes.
Cite This Study
Peter Libby (2017) conducted a review in Atherosclerosis. Anti-inflammatory therapies targeting Interleukin-1 beta (IL-1β) was evaluated. Interventions targeting interleukin-1 beta (IL-1β) can improve cardiovascular outcomes, supporting the use of anti-inflammatory therapies for atherosclerosis.